A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Ramipril
- Indications Diabetic nephropathies; Proteinuria; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms DEER
- 31 Aug 2018 Biomarkers information updated
- 03 Dec 2015 Planned End Date changed from 19 Jun 2016 to 1 Nov 2015 as reported by United Kingdom Clinical Research Network.
- 03 Dec 2015 Status changed from not yet recruiting to recruiting as reported by United Kingdom Clinical Research Network.